Arcis Biotechnology

Arcis Biotechnology enables earlier, more accurate cancer detection. The business successfully closed its SyndicateRoom round in 2018.

The story

Obtaining genetic material from biological samples is a critical step in molecular biology which is often time-consuming and inefficient, typically taking between 24–72 hours.


In less than 3 minutes and with no prior sample preparation, Arcis' products allow users to quickly and conveniently go from "raw" biological material to processed nucleic acid that is ready for investigation.

Alongside capitalising on an $18.1bn market opportunity, the implementation of Arcis' technology could save the lives of sufferers who are, unfortunately, otherwise diagnosed too late for effective treatment.

arcis_hand (1).jpg

The team

A qualified chartered accountant by background, Peter Whitehurst is Arcis Biotechnology's CEO. Peter was a key member of the SSL executive team that accepted an acquisition bid from Reckitt Benckiser for £2.54bn in 2010. He thrives on building high-performing teams and giving them the remit, funds and business focus to produce tangible results.

The lead investor

Andrew Parker is a pharmacist by training, whose career highlights include being a director and shareholder of PCT Healthcare Holdings. He is currently both a supporter and investor in various life science companies.

Investor testimonials

I have invested in a number of Arcis’ investment rounds due to the strength of the IP, the resilience of the team and their ability to create strategic value.

David E.


See current opportunities